Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-acetylcysteine (NAC) Clear all
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Mucinex Exploratory Cold Study

NCT01046136
View directory record Official record
Conditions
Common Cold
Interventions
guaifenesin (Mucinex), placebo
Drug
Lead sponsor
Reckitt Benckiser Inc.
Industry
Eligibility
12 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bellevue, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Sinusitis

NCT00377403
View directory record Official record
Conditions
Acute Respiratory Infections, Acute Rhinosinusitis
Interventions
Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 11, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

NCT01251315
View directory record Official record
Conditions
Oxidative Stress
Interventions
Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Early Phase 1 Interventional

NAC Trial for Anosmia

NCT02481609
View directory record Official record
Conditions
Anosmia
Interventions
N-acetyl cysteine (NAC)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

NCT00440869
View directory record Official record
Conditions
End-Stage Renal Disease, Dialysis, Hemodialysis
Interventions
N-acetylcysteine, placebo
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2010 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

NCT04887194
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

NCT04291066
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
N-Acetyl cysteine
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine for Pediatric Trichotillomania

NCT00993265
View directory record Official record
Conditions
Trichotillomania, Hair Pulling
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

NCT03500627
View directory record Official record
Conditions
Healthy
Interventions
OP-101
Drug
Lead sponsor
Orpheris, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 11, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional

FDOPA PET and Nutritional Support in Parkinson's Disease

NCT04459052
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 3 Interventional

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

NCT04300920
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Fernando J Martinez
Other
Eligibility
40 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

NCT00539188
View directory record Official record
Conditions
Borderline Personality Disorder, Self-Injurious Behavior
Interventions
N-Acetylcysteine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 11, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

NCT05122559
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Emmanuelle Waubant, MD PhD
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence

NCT01214083
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
West Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 11, 2026, 6:14 AM EDT
Completed No phase listed Observational

Treatment of Acetaminophen Toxicity With N-acetylcysteine

NCT00725179
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2011 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Not applicable Interventional

The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease

NCT00498342
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

NCT00218491
View directory record Official record
Conditions
Cocaine Dependence
Interventions
N-Acetylcysteine, Matching Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

NCT00585559
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
20 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 11, 2026, 6:14 AM EDT
Terminated Early Phase 1 Interventional

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

NCT04703036
View directory record Official record
Conditions
Covid19
Interventions
Glycine, N-acetylcysteine, Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 11, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 11, 2026, 6:14 AM EDT